Effect of Pravastatin on Survival in Advanced Liver Cancer
Author Information
Author(s): Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y
Primary Institution: Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University
Hypothesis
Does pravastatin prolong survival in patients with advanced hepatocellular carcinoma?
Conclusion
Pravastatin significantly prolonged the survival of patients with advanced hepatocellular carcinoma.
Supporting Evidence
- The study included 91 patients, with 83 completing the trial.
- Median survival was 18 months for the pravastatin group compared to 9 months for the control group.
- Pravastatin was administered at a daily dose of 40 mg.
Takeaway
This study found that a medicine called pravastatin can help people live longer when they have a serious liver cancer.
Methodology
A randomized controlled trial with 91 patients, where 83 were treated with standard care plus pravastatin or standard care alone.
Limitations
Some patients were withdrawn due to liver dysfunction, and the study was limited to patients under 71 years old.
Participant Demographics
91 consecutive patients under 71 years old with unresectable hepatocellular carcinoma.
Statistical Information
P-Value
0.006
Statistical Significance
p=0.006
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website